NEW YORK (GenomeWeb) – ArcherDx and GenomOncology today announced an agreement to co-market ArcherDx's next-generation sequencing assays alongside GenomOncology's data interpretation software.

Under the terms of the agreement, GenomOncology's GO Clinical Workbench will support interpretation of several ArcherDx assays, including the ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung panels.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more